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Mitochondria are semi-autonomous organelles regulated by a complex network of proteins that are vital for
many cellular functions. Because mitochondrial modulators can impact many aspects of cellular
homeostasis, their identification and validation has proven challenging. It requires the measurement of
multiple parameters in parallel to understand the exact nature of the changes induced by such compounds.
We developed a platform of assays scoring for mitochondrial function in two complementary models
systems, mammalian cells and C. elegans. We first optimized cell culture conditions and established the
mitochondrial signature of 1,200 FDA-approved drugs in liver cells. Using cell-based and C. elegans assays,
we further defined the metabolic effects of two pharmacological classes that emerged from our hit list, i.e.
imidazoles and statins. We found that these two drug classes affect respiration through different and
cholesterol-independent mechanisms in both models. Our screening strategy enabled us to unequivocally
identify compounds that have toxic or beneficial effects on mitochondrial activity. Furthermore, the
cross-species approach provided novel mechanistic insight and allowed early validation of hits that act on
mitochondrial function.
M
itochondrial dysfunction not only typifies a range of rare inherited mitochondrial diseases1,2, but it has
become clear that defects in mitochondrial function are also associated with age-related disease3. The
concept of maintaining or repairing mitochondrial function may hence offer new preventive and
therapeutic strategies for several of these rare and common diseases that still require efficient treatments.
Amongst themodels that are available to exploremitochondrial defects and therapeutics, themouse is themost
widely used because of the existence of a powerful genetic toolkit and the physiological similarities to humans4,5.
For example, mitochondrial defects of COX-deficient mice can be reversed using the AMPK agonist AICAR6.
Other compounds targeting similar pathways, i.e. resveratrol and nicotinamide riboside, restore mitochondrial
function in mice fed with a high-fat diet7–10. Notably, the beneficial effects of resveratrol also applied to human
fatty acid oxidation-deficient fibroblasts11 and obese patients12. C. elegans is also used to study mitochondria,
especially in the context of longevity13–16. The worm lives only weeks versus years for mice, while the ease of
genetic modifications render the exploration of mitochondrial pathways accessible. Unfortunately, however,
mouse and worm models are limited in throughput, precluding screening for new mitochondrial drugs3. One
of the alternative approaches that has been developed in recent years involves phenotypic screening in both
primary and immortalized cell lines3,17–19. These studies have shown that it is possible to identify compounds that
impact on mitochondrial function without targeting a specific molecular pathway. Nevertheless, this type of
approach requires a solid set of validated follow-up assays to elucidate howmitochondrial modulators work, and
to narrow down several dozens of hits to compounds that are worth testing in animals.
Here, we report the development of an assay platform composed of mouse liver cells (Hepa1.6) and C. elegans
for the systematic identification and characterization of compounds that improve mitochondrial metabolism
(Figure 1). These assays are intended to assess compounds for their efficiency or toxicity on mitochondrial
function. To validate our method, we first optimized cell culture conditions to ensure that the cells relied on
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oxidative metabolism. We next identified compounds with a strong
impact on mitochondrial function out of the,1,200 FDA-approved
drugs in liver cells using a phenotypic strategy similar to that
developed previously17. Two pharmacological classes of compounds
emerged in our hit list, imidazoles and statins. We further character-
ized the effect of these two pharmacological classes onmitochondrial
function using our set of assays. In summary, our study reports the
potential of the use of an intact organism, such as C. elegans, in
combination with mammalian cells to identify and validate hits that
affect mitochondrial function at a very early stage of the drug dis-
covery process.
Results
Designing a multi-level screening platform inmammalian cells and
C. elegans.We developed a platform of assays using mammalian cells
and C. elegans to identify and validate compounds that modulate
mitochondrial function (Figure 1A–B). As a starting point, we
adapted a phenotypic high-throughput screening strategy that was
developed and initially validated in muscle cells17. During the
screening and validation of mitochondrial modulators, the main
objective is to rapidly establish the toxicity and efficacy of the
compound. Several cell culture assays were employed for this
purpose. For example, measurement of ATP levels is a robust way
to assess toxicity17,20 (Figure 1A–B). Metabolic redox balance, such as
NAD1/NADH ratio (Figure 1A–B), can be measured indirectly with
the use of fluorescent redox probes21. Nicotinamide adenine dinucleo-
tide (NAD1) is not only a cofactor involved in the redox reactions, but
it is also a co-substrate of the sirtuin family of deacetylases, which
control mitochondrial metabolism at various levels22 (Figure 1B).
Fluorescent probes that accumulate inside mitochondria propor-
tionally to mitochondrial membrane potential (DyM) and mitochon-
drial abundance (e.g. tetramethylrhodamine or TMRM) can inform
both about efficacy and toxicity of compounds23 (Figure 1A–B). Once
hits are identified in this initial screen, the optimal dose for each
compound can be determined in cells by using the same assays as
used during high-throughput screening (Figure 1A). Mitochondrial
bioenergetics, or energy flow through mitochondria, is then assessed
by monitoring oxygen consumption and lactate production18,19
(Figure 1A–B). All these assays are transposable to almost every cell
line, although they are representative only of the effect of a compound
on the tissue from which the cell line is derived.
In this regard,C. elegans offers the possibility to score the impact of
compounds on mitochondria and physiological homeostasis at the
scale of an entire organism. A first and easy parameter to assess
toxicity of a compound is to look at its impact on worm development
(Figure 1A). Indeed, mitochondrial mutants were shown to have
either impaired or delayed larvae growth14. To further characterize
mitochondrial bioenergetics, oxygen consumption can also be mea-
sured in worms13 (Figure 1A–B).
In our model, we propose that only compounds with effects on
mitochondria in bothmodels are further validated inmore expensive
and time-consuming assays in both species (Figure 1A).
Optimization of the cell culture conditions. We developed our
mammalian assays in the mouse hepatocyte cell line Hepa1.6, a cell
line that is robust and easy to culture, and is derived from a tissue
where mitochondria are abundant. We first optimized cell culture
conditions to ensure that the cells solicit mitochondria to produce
energy. We monitored cellular energy utilization by comparing
different nutrient sources, 1) high glucose (5 g/l, HG); or 2) low
glucose (1 g/l) supplemented with 30 mM oleic acid (LGO)
(Figure 2A). While HG can be metabolized through glycolysis and
mitochondrial oxidation, LGO forces the cells to actively rely on
mitochondrial function. Indeed, LGO medium induced a marked
decrease in two assays indicative of glycolysis, including redox poten-
tial, which is sensitive to NAD1/NADH ratio, and extra-cellular
acidification rate (ECAR), a marker of lactate production (Figure 2A),
In contrast, ATP level and oxygen consumption rate (OCR) were both
increased in LGOmedium (Figure 2A).We also observed an increase in
the NAD1/NADH ratio in Hepa1.6 cells grown in LGO, in agreement
with reduced redox potential (Figure 2B). These results show that LGO
medium induces a metabolic shift from glycolysis to oxidative
phosphorylation (OXPHOS).
We next tested whether cell confluence impacts on Hepa1.6 meta-
bolismbymeasuringOCR andECAR at different levels of confluence
(Figure 2C). While OCR increased with cell number, ECAR
Figure 1 | Assays platform for the identification and validation of novel mitochondrial modulators. (A) Workflow to assess mitochondrial function
going from hundreds of compounds to the best candidates (top to bottom) in mammalian cells and C. elegans. After hits have been identified during a
high-throughput screening, they are assessed for their efficiency and toxicity on mitochondrial function using this assay platform. Once the best
candidates have been sorted out, they can be further investigated in both models, and ultimately in vivo. (B) The different pathways that are assessed and
the respective markers that were measured (black boxes). This scheme is non-exhaustive and represents only the key regulatory steps that are surveyed.
More details can be found in the main text.
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decreased until a certain threshold, suggesting thatHepa1.6 cells shift
from glycolysis to OXPHOS to produce ATP as confluence increases
(Figure 2C). To confirm this observation, we treated Hepa1.6 cells at
different cell confluences for 24 hours with the mitochondrial ATP
synthase inhibitor oligomycin, and measured residual ATP levels
(Figure 2D). In line with our results on themetabolic switch at higher
confluence, these cells were insensitive to high doses of oligomycin at
low confluence, while becoming sensitive at higher confluence
(Figure 2D). Based on these results, we decided to perform all assays
when the cells are at 95% confluence and using LGO as cell culture
medium.
Screening of the Prestwick library of FDA-approved drugs in
Hepa1.6 cells. For the full validation of our high-throughput
screen (HTS) we tested viability (ATP level), redox potential and
mitochondrial membrane potential (Dym) in Hepa1.6 cells
exposed to a collection of ,1,200 mostly FDA-approved drugs in
the Prestwick library (Figure 3). We obtained good separation
capacity for ATP and redox potential, with a Z-factor of 0.58 and
0.85, respectively, while the Dym assay had a Z-factor of 0.01,
suggesting that this assay could potentially lead to more false
positives and negatives (Figure 3A). The absence of significant
correlation between the different parameters shows that the assays
are complementary and non-redundant (Figure 3B–C).
Compounds were considered as hits when inducing a signal
change superior to DMSO 6 2sDMSO and when deviating from
normal distribution, i.e. when squared distance between observed
quantile and theoretical quantile was above a certain threshold
(Figure 3D–E, methods section). 53 hits were identified after apply-
ing this two-steps selection method (Figure 4A). Hierarchical clus-
tering was used to identify the different profiles of the hits, i.e. the
combinations of the scores in each of the assays (Figure 4A). We
focused our subsequent validation work on pharmacological classes
that were enriched in our screen by profiles. This strategy increased
our chances to characterize an effect that is due to the common
mechanism of action of a pharmacological class, rather than an
off-target effect of an isolated compound. One cluster contained
six hits that were particularly toxic to the cells, as all three parameters
decreased (Figure 4A–B). It included the antineoplastic drug camp-
tothecine (S,1), and niclosamide, which has been reported to inhibit
OXPHOS directly24 (Figure 4A–B). A larger cluster encompassed
compounds that increased redox potential, without affecting ATP
or Dym (Figure 4A and C). Amongst these compounds, five belong
to the class of antifungal imidazoles (Figure 4A and C). Imidazoles
block demethylation of lanosterol through the inhibition of sterol
14a-demethylase (CYP51A1)25,26, an essential step in the synthesis of
ergosterol in fungi and cholesterol in mammals. Other reports show
that their antifungal effect is also mediated by an induction of
uncoupling and swelling of rat liver mitochondria27. Imidazoles
henceforth represent a class of compounds that are potentially toxic
to the mitochondria. A third remarkable cluster regrouped com-
pounds that induce Dym, without affecting ATP or redox potential
(Figure 4A and D). Strikingly, this set of Dym inducers contained
three statins (Figure 4A and D). Statins inhibit one of the initial steps
in cholesterol biosynthesis, but this also affects the synthesis of coen-
zyme Q10 (CoQ10), heme-A and substrates for protein prenyla-
tion28. Therefore, statins represent a class of compounds that may
also induce mitochondrial stress, but have an overall demonstrated
beneficial impact on human health and longevity29.
Considering the overrepresentation of statins and imidazoles in
our hit list, we decided to further characterize their effect on mito-
chondrial function using our mammalian and C. elegans assays
(Figure 1A).
Impact of imidazoles on metabolism in cultured cells and C.
elegans. We first performed dose-response tests for all our mam-
malian assays using the four imidazoles identified, i.e. econazole,
miconazole, tioconazole and bifonazole (Figure 5A–H). Tiocona-
zole and bifonazole showed toxic effects on ATP levels, but only at
30 mM (Figure 5A). Miconazole and bifonazole increased redox
potential by up to 50% at 10 and 30 mM, while econazole and
tioconazole gave milder responses (Figure 5B). All four imidazoles
decreased Dym by at least 50% at 10 and 30 mM (Figure 5C). The
reason why these compounds did not decrease Dym significantly
during theHTS (Figure 4A and C) is explained by the high variability
of this assay, leading to a higher threshold of significance when
testing multiple samples. All these changes were independent on
cell number, as assessed by DNA quantification (Figure 5D). Long-
term treatment of Hepa1.6 (24 hours) cells with imidazoles induced
a metabolic shift toward glycolysis, as ECAR was maintained
(Figure 5E) while basal OCR significantly decreased (Figure 5F).
Uncoupled OCR was also significantly reduced after imidazoles
treatment, indicating a decrease in maximal respiratory capacity
(Figure 5G). Measurement of OCR after short-term treatment
showed that econazole, miconazole and bifonazole inhibit cellular
respiration within a few minutes (Figure 5H), suggesting that
imidazoles inhibit the mitochondria directly and acutely. This
toxic effect of imidazoles was confirmed in C. elegans, as they all
strongly disturbed worm development at 10 mM and higher doses
(Figure 5I).
The fact that C. elegans are cholesterol auxotrophs and are supple-
mented with cholesterol during the experiments27,30,31 underscores
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that the imidazole toxicity is independent of cholesterol depletion.
Instead, imidazoles have an acute inhibitory effect on respiration, in
line with previous reports27. A potential explanation for this effect is
the inhibition of the transient receptor potential cation channel,
subfamily M, member 2 (TRPM2), a calcium-permeable cation
channel that is regulated by free intracellular ADP-ribose32.
Importantly, even though the imidazoles are toxic in our experi-
mental setup, they are mostly used topically in the clinic. In such
application, less than 1% reaches the systemic circulation33, which
explains why this is unlikely to cause major systemic side effects.
Impact of statins on metabolism in cultured cells and C. elegans.
Similar to our strategy for imidazoles, we first performed dose-
response studies for redox potential, ATP level and Dym using the
different statins (Figure 6A–C). All three statins induced Dym by up
to 3-fold in Hepa1.6 cells, indicating a strong hyperpolarization,
while ATP level and redox potential did not change (Figure 6A–
C). The effect on Dym was not due to an increase in the number
of cells, which was only mildly increased at the highest dose with
atorvastatin and simvastatin (Figure 6D). Treatment of Hepa1.6 cells
for 24 hours with fluvastatin and simvastatin decreased both OCR
and ECAR, but only OCR with atorvastatin (Figure 6E–F),
suggesting an overall decrease in metabolic rate of the cells. The
decrease in OCR was maintained when OXPHOS was uncoupled
(Figure 6G), indicating a decrease in overall respiratory capacity.
However, unlike imidazoles, statins did not inhibit respiration in
Hepa1.6 cells acutely (Figure 6H).
The effect of statins was further investigated in C. elegans using
fluvastatin. This statin was selected as simvastatin and atorvastatin,
but not fluvastatin, crystallized at 20 mM in the agar plates used for
worm culture. Although high doses of statins (mM) lead to embry-
onic lethality in worms due to the impaired prenylation of small
GTPases34, we found that fluvastatin did not impair larval develop-
ment up to the concentration of 50 mM (Figure 6I). We then tested
the effect of fluvastatin on worm respiration (Figure 6J–K). While
basal OCRwas similar to untreated worms, addition of FCCP did not
Figure 3 | Screening of 1,200 FDA approved drugs in the Hepa1.6 cell line. (A–E) Screening of the Prestwick library of FDA approved drugs, using the
three basal assays and oxidative cell culture conditions, i.e. low glucose concentration (1 g/l), supplementation with oleic acid at 30 mMand cell density of
95% the day of the assays. (A) Cell-based assays screening separation bandwidth. Plots represent the cumulative density of points over Z scores of the raw
values for all the points of the screening, including negative (blue points) and positive controls (red points) and samples. The redox potential assay has the
best separation capacity with narrow peaks of negative and positive controls on the density plot and a Z factor close to 1. (B–C) Correlations between the
three cell-based assays show poor level of relationship between the different parameters. (B) Pearson’s r correlation coefficients and their corresponding
regression r2 value were calculated for normalized ratios of the three parameters. (C) Spearman’s r correlation coefficient was calculated for the
correlation between rank orders of every parameter. (D) Graphs represent the normalized ratio calculated as described in the materials and methods
section. The black lines delimit the zone of compounds inducing a change inferior to DMSO 6 2sDMSO, and the red lines the zone of compounds
inducing a change superior to DMSO 6 3sDMSO. (E) Graphs represent the quantile-quantile (QQ) plots, plotting the theoretical quantiles for each assay
in x-axis over the normalized ratio in y-axis. The grey points correspond to compounds inducing a change inferior to DMSO6 2sDMSO, the black points
to a change comprised between DMSO 6 2sDMSO and DMSO 6 3sDMSO, and the red points to a change superior to DMSO 6 3sDMSO.
www.nature.com/scientificreports
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increase OCR in fluvastatin-treated worms (Figure 6J–K), suggesting
that the impact of statins on respiration was conserved through the
different models. Finally, fluvastatin increased worm mean lifespan
by 14% at 20 mM and by 13% at 50 mM (Figure 6L), indicating that
the decrease in respiration induced by fluvastatin has an overall
beneficial effect in worms.
A potential mechanism to explain the decreased respiratory capa-
city in cells and worms after long-term statin treatment is the inhibi-
tion of mevalonate synthesis, which in turn limits CoQ10 and
heme-A levels28, two essential components of the mitochondrial res-
piratory chain35. Another possibility is that these effects are mediated
at the transcriptional level. To test this hypothesis, we analyzed a
dataset from the Connectivity Map database (http://lincs.hms.
harvard.edu/db/). This data set contains gene expression profiles
of the human breast cancer cell line MCF-7 exposed for 6 hours to
three different statins, i.e. fluvastatin, simvastatin and lovastatin at
10 mM. The change in gene expression after statin treatment was
low because of the limited number of samples per condition
(Figure 7A). As expected, genes involved in cholesterol biosynthesis
were strongly upregulated (Figure 7B). Additionally, we noted a
significant downregulation of genes involved in mtDNA transcrip-
tion (Figure 7C).
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As a further translation of our data towards human relevance, we
performed a gene-set enrichment analysis on gene expression data
from 480 patient-derived lymphoblastoid cell lines that were exposed
for 24 hours to vehicle or 3 mM simvastatin36. The overall gene
expression variation in these cells after simvastatin treatment was
low, but due to the high number of samples per conditions, 26% of
genes presented a significant change (Figure 7D). Similar to the
Connectivity Map data, the cholesterol biosynthesis pathway was
strongly induced by simvastatin (Figure 7E)36,37, and several mito-
chondrial gene sets related to mtDNA transcription were downre-
gulated (Figure 7F). In addition, expression of genes related to
respiratory complex I and V were also repressed (Figure 7F). These
data suggest that the mitochondrial functional changes we observed
in mouse hepatocytes and worms are conserved in humans and are
common to at least fluvastatin, simvastatin and lovastatin.
Discussion
We developed a set of straight-forward assays in two different model
systems to rapidly identify whether a compound may have potential
therapeutic benefits at the level of mitochondria.
The first model is an immortalized hepatic cell line, Hepa1.6.
Immortalized cell lines offer the advantage that they can be grown
in large quantities and high number of passages, two features that
make their use easier when working at a high-throughput level.
However, the immortalization process is accompanied by metabolic
changes similar to those observed in cancer cell lines, including the
presence of the so-called Warburg effect38. A careful optimization of
cell culture conditions is therefore required to ensure that the cells
rely on mitochondrial metabolism for energy production.
Supplementing oleic acid in the culture medium and increasing cell
confluence stimulated Hepa1.6 cells to switch from glycolytic to
mitochondrial metabolism (Figure 2). In this cell line, we measured
several parameters that displayed a wide dynamic range during our
screening. This allowed the identification of both activators and
inhibitors of mitochondrial function. In fact, we were able to stratify
the hits according to their response and divided into them separate
classes, i.e. compounds toxic to mitochondria and cells (e.g. papa-
verine, niclosamide), compounds that induce redox potential (imi-
dazoles) and those that induce Dym signal (statins).
Hits from our high-throughput screening were selected for the
evaluation of respiration and lactate production. The increase in
the throughput of the respiration assays enabled the measurement
of up to four parameters related to catabolism (ECAR, basal OCR
and uncoupled OCR after long-term treatment, and OCR after acute
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treatment). Notably, the determination of OCR after acute incuba-
tionwith the compounds allowed us to distinguish between the direct
impact of imidazoles onmitochondria versus the indirect effect of the
statins on respiration, only evident after long-term treatment.
The second model that we used to analyze mitochondrial function
was the roundworm C. elegans. It has the advantage to provide
insights on the effects of compounds in an intact animal and at the
scale of multiple tissues. One of our read-outs was the impact of
compounds on larval development. C.elegans development depends
on the accurate timing of cell division and differentiation, which
requires a complex combination of genetic and molecular mechan-
isms39. In particular, development of C.elegans is highly energy-
dependent and relies on the electron transport chain (ETC), as it
was shown that food deprivation and downregulation of ETC com-
plexes expression strongly delayed or stopped the larval develop-
ment40. In line with these premises, imidazoles, but not statins,
caused a severe developmental delay. Since C. elegans are cholesterol
auxotrophs, our data suggest that the toxicity of the imidazoles is
independent of cholesterol depletion. Instead, imidazoles have an
acute inhibitory effect on respiration, whichmay be due to the induc-
tion of uncoupling and swelling ofmitochondria, as previously docu-
mented in isolated rat liver mitochondria exposed to econazole27.
In contrast, the mechanism by which statins affect mitochondrial
respiration was not associated with toxicity, as Hepa1.6 cells were
able to maintain their ATP and redox potential levels, and worm
development was not impacted. Our result hence contrasts with
previous reports showing that high pharmacological doses of statins
inhibitC. elegans development34.We used, however, at least ten times
lower doses, and stayed below doses at which the hydrophobic flu-
vastatin crystallizes in agar plates. Working in these more gentle and
physiological conditions, we were able to show for the first time that
fluvastatin increased worm lifespan, in line with the lifespan exten-
sion observed in Drosophila and the reduction in all-cause mortality
measured in humans after simvastatin treatment41–44. Remarkably,
the fact that statins extend lifespan in lower organisms suggests that
their therapeutic benefit in humanmay also be partly independent of
their effect on cholesterol biosynthesis.
Two potential mechanisms can explain the decreased respiratory
capacity in cells and worms after long-term statin treatment. First, by
inhibiting mevalonate synthesis, statins also impact on the levels of
CoQ10 and heme-A28, which are both essential for respiratory chain
function35. Second, gene expression data from both lymphoblastoid
cell lines andMCF-7 cells show that there is also a downregulation of
genes involved in mtDNA transcription. In the lymphoblastoid cell
lines, there is furthermore a pronounced decrease in the expression
of genes encoding for components of complex I and V subunits. The
link between these data and the increase in Dym after statins is less
clear. In fact, Dym is decreased in cells with defects in respiratory
complexes I and II45,46. However, another study showed that in neu-
rons deficient for respiratory complex I, Dym was increased because
ATP synthase is working in reverse mode47. Overall, these data
underline the complexity of the metabolic remodeling induced by
statins treatment. This complexity is directly linked to the number of
pathways affected by the inhibition of mevalonate synthesis, which is
an early precursor of multiple metabolites.
In conclusion, we developed a cross-species mitochondrial screen-
ing and validation platform, using both mammalian cell lines and C.
elegans, exploiting and emphasizing the strengths of each of these
models. Using this screen, we identified negative and positive regu-
lators of mitochondrial function. The combination of multiple tests
that inform about distinct aspects of mitochondria enabled us to
define a complex and comprehensive signature of the actions of
pharmacological compounds on mitochondria. This setup allowed
us to define the effects of imidazoles and statins on mitochondrial
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function, and identify potential novel pathways that may contribute
to the pleiotropic effects observed upon statin treatment. We envi-
sion that such a comprehensive screening approach is essential to
identify novel mitochondrial modulators. Such compounds will be
beneficial for both rare and common diseases in whichmitochondria
are dysfunctional.
Methods
Compounds used in cell-based assays and C. elegans. The Prestwick Chemical
Library, which contains 1,200 small molecules and FDA approved drugs, was
acquired at Prestwick Chemicals (Illkirch-Graffenstaden, France). Fluvastatin,
simvastatin and atorvastatin were provided by Prestwick Chemicals (Illkirch-
Graffenstaden, France). Econazole, miconazole, tioconazole and bifonazole were
acquired at Sigma (Sigma-Aldrich, St. Louis, MO, USA).
Cell lines and medium conditions. Hepa1.6 mouse hepatoma cells were obtained
from ATCC and maintained according to ATCC guidelines. For the assays, hepa1.6
cells were plated in low glucose medium (1 g/l glucose) supplemented with 30 mM
oleate-BSA (LGO) (Sigma-Aldrich, St. Louis, MO, USA), unless specified otherwise.
High-throughput cell-based assays.Hepa1.6 cells were seeded at 8,000 cells per well
in a volume of 15 ml, in 384-well plates. Compounds and were added from a 4x
concentrated stock, diluted in culture medium, to the cells, reaching a total assay
volume of 20 ml. Assays were typically performed 24 hours after incubation with
medium or compounds. ATP levels were measured using Cell Titer Glo (Promega,
Madison,WI, USA). Mitochondrial membrane potential (Dym)was measured using
the fluorescent tetramethylrhodamine methyl ester (TMRM) probe (T-668,
Invitrogen, Paisley, UK). Briefly, cells were incubated in culture medium and TMRM
was added to the culture medium at a final concentration of 200 nM for 45minutes at
37uC before washing with 50 ml of PBS. The Alamar Blue assay (Life Technologies,
Paisley, UK) was used as a marker for redox potential, following manufacturer
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Figure 7 | Impact of simvastatin on gene expression inMCF-7 cells and human lymphoblastoid cell lines. (A–C) Effect of three statins, fluvastatin (Flu.),
lovastatin (Lov.) and simvastatin (Sim.), on gene expression in MCF-7 cells after 6 hours treatment at 10 mM. (A) Vulcano plot of microarray dataset.
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protocols. ATP level, redox potential and TMRM assays were measured on a Tecan
Infinite 500 (Tecan, Ma¨nnedorf, Switzerland), and performed in duplicate.
Screening of a 1,200 drugs library - specific procedures.Hepa1.6 cells were seeded
at 8,000 cells per well, in a volume of 20 ml, in 384-well plates, treated on day 1 using a
Sciclone G3 Liquid Handling Workstation (PerkinElmer, Waltham, MA, USA) and
distributing a volume of 2.22 ml of compounds at 100 mM to obtain a final
concentration of 10 mM in each well. Assays were performed after 24 hours of
incubation with compounds. For ATP level, redox potential and TMRM assays, we
used DMSO at 0.1% as a negative control (final DMSO concentration in all wells) and
oligomycin A at 1 mMas a positive control, both of them being present on each side of
all the plates, i.e. columns 23–24 and 1–2 respectively. These assays were performed in
duplicate.
High-throughput screening data were analyzed using the cellHTS2 package fromR
software (http://www.r-project.org/). ATP, redox potential and TMRM, data were
normalized per plate using the normalized percentage of inhibition function (nor-
malized ratio), calculated as follows: xNPIki ~
m
pos
i {xki
m
pos
i {m
neg
i
, where xki is a result point, m
pos
i
is the average for all the oligomycin A positive control points and mnegi is the average of
the DMSO negative control points. Z scores and Z factors were calculated from these
normalized values for the Figure 3A. Theoretical quantiles (Figure 3E)were calculated
from the normalized values using R software. Compounds were considered as hits
when inducing a signal change superior to DMSO 6 2sDMSO and when deviating
from normal distribution, i.e. when squared distance between observed quantile and
theoretical quantile was above a certain threshold. This threshold was arbitrarily set at
s^2§0:005 for ATP, TMRM and redox potential signals. Clustering of the 53 hits was
performed on the Hierarchical Clustering module available on the GenePattern
website (http://www.broadinstitute.org/cancer/software/genepattern), using
Euclidean distance and single linkage as analysis parameters.
Measurement of cellular NAD1 and NADH levels. NAD1 and NADH levels were
determined using the EnzyChromTM NAD/NADH Assay kit and following
manufacturer’s instructions (BioAssays Systems, Hayward, CA, USA)
Measurement of DNA levels per cell. DNA was measured directly in Seahorse 96-
well plates using the CyQUANTH Cell Proliferation Assay Kit and following
manufacturer’s intructions (Lifetechnologies, ThermoFisher Scientific, Waltham,
MA, USA).
Measurement of cellular and C. elegans respiration. Oxygen consumption rate
(OCR) and extra-cellular acidification rate (ECAR) were measured using the
Seahorse XF96 equipment (Seahorse bioscience Inc., North Billerica, MA, USA). For
measurement of cellularmetabolism, Hepa1.6 were seeded at 12,000 cells per well and
treated with different medium conditions or compounds for 24 hours in 150 ml
medium. Acute effect of compounds was evaluated by injecting them during the run.
Worm oxygen consumption was performed as described48. Briefly, at day 1 of
adulthood, ten worms per well were transferred into M9-filled 96-well Seahorse
plates. Oxygen consumption was measured 6 times in basal conditions. FCCP
treatment was performed at 10 mM final.
Pharmacological treatment of C. elegans strains. C. elegans strains were cultured at
20uC on nematode growth media agar plates seeded with E. coli strain HT115 (DE3).
Strains used were wild-type Bristol N2 and provided by the Caenorhabditis Genetics
Center (University of Minnesota). Imidazoles and statins were added at the indicated
concentrations just before pouring the plates. Animals were exposed to compounds
during the full life from hatching onwards. To ensure a permanent exposure to the
compound, plates were changed twice a week for the lifespan assays. Imidazoles and
statins were dissolved in DMSO, and the vehicle controls were adapted accordingly.
Lifespan and development assays. Lifespan tests were performed as described at
20uC49. Briefly, 60–100 animals were used per conditions and scored every other day.
Animals that crawled off the plate or had an «exploded vulva» phenotype were
censored. The development of a synchronized worm population was monitored after
4 days of post-embryonic development by taking pictures of the whole plate.
Worm statistics. Survival analyses were performed using the Kaplan Meier method
and the significance of differences between survival curves calculated using the log
rank test. Calculation of mean lifespan and SEMwere calculated using the R software.
Bioinformatics analysis. The datasets generated in human lymphoblastoid cell
lines36 was downloaded fromGene Expression Omnibus under the accession number
GSE36868. The datasets generated in the human breast cancer cell line MCF-7 was
downloaded from the Connectivity Map database (http://lincs.hms.harvard.edu/db/).
Data were first normalized with RMAExpress software (http://rmaexpress.
bmbolstad.com/) and analyzed using the Gene Set Enrichment Analysis software50.
The cholesterol synthesis geneset was defined according to GO annotation
(Accession number: 0006695). In this case, since a single gene set was tested (e.g.
cholesterol gene set), a nominal p value inferior to 0.05 was used as significance
threshold. Mitochondrial genesets were defined by searching for all gene ontologies
containing the word ‘‘mitochondria*’’ on AmiGO website (http://amigo.
geneontology.org/cgi-bin/amigo/go.cgi). A total of 121 genesets were defined using
this method. In this case, several genesets were tested and the q value of the false
discovery rate control inferior to 0.25 was used as a significance threshold.
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